Probiotics and Influenza Vaccination Response (VERB)
Effects of Probiotics in Immune Response to Influenza Vaccination in Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Vineetha Vijayakumar, PhD
- Phone Number: 07885966211
- Email: vineetha.vijayakumar@adm.com
Study Locations
-
-
-
Ede, Netherlands
- Alwine Kardinaal, PhD NIZO food research B.V
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women
- Age 16 - 65 y and healthy
- Self-reported regular Dutch eating habits as assessed by questionnaire (3 main meals per day)
- No influenza vaccination in 2022
- Non-smokers
- BMI 18.5-28
- Adherence to habitual diet
- no changes during study period
- Signed informed consent
Exclusion Criteria:
- Recent vaccination
- Acute or chronic illness (e.g., diabetes mellitus)
- Gastrointestinal disorders (e.g., inflammatory bowel disease)
- Acute gastroenteritis in the past 2 months
- Immunodeficiency disorder
- Use of immunosuppressive drugs (e.g. cyclosporine, azathioprine, systemic corticosteroids, antibodies)
- Unexplained weight loss or weight gain of > 3 kg in the 3 months prior to pre-study screening
- Alcohol or drug abuse
- Mental status that is incompatible with the proper conduct of the study
- History of cancer
- Use of immune boosting supplements within 4 weeks before screening To be extended & specified in protocol phase
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotic
2B Colony Forming Unit/ day
|
Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from >10 to 40 in Ab titre for seronegative subjects.
|
|
Placebo Comparator: Placebo
Equivalent placebo
|
Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from >10 to 40 in Ab titre for seronegative subjects.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Seroconversion rate
Time Frame: From baseline to week 6
|
Percentage of subjects achieving at least a 4-fold increase or an increase from >10 to 40 in Antibody titer for seronegative subjects
|
From baseline to week 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in plasma cytokine levels
Time Frame: Baseline, week 2 and week 6
|
Change in plasma cytokine levels (IL-10, IL-4, TFN alpha, IFN gamma)
|
Baseline, week 2 and week 6
|
|
Change in IgA antibodies against influenza
Time Frame: baseline, week 2, week 6
|
Titer of plasma anti-influenza IgA
|
baseline, week 2, week 6
|
|
Change in IgG antibodies against influenza
Time Frame: baseline, week 2, week 6
|
Titer of plasma anti-influenza IgG
|
baseline, week 2, week 6
|
|
Change in IgM antibodies against influenza
Time Frame: baseline, week 2, week 6
|
Titer of plasma anti-influenza IgM
|
baseline, week 2, week 6
|
|
Change in Gastrointestinal symptoms
Time Frame: baseline, week 2, week 6
|
Gastrointestinal manifestations documented through Gastrointestinal Symptom Rating Scale (GSRS, 7-point graded Likert-type scale and includes 15 items combined into 5 symptom clusters - 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms)
|
baseline, week 2, week 6
|
|
Change in Incidence of respiratory infections
Time Frame: baseline, week 2, week 6
|
Assessment of respiratory infection through questionnaire (4-point graded Likert-type scale and includes 11 items, including the 8 items comprising the Jackson common cold questionnaire - 0 = absent, 1 = mild, 2 = moderate, 3 = severe)
|
baseline, week 2, week 6
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Alwine Kardinaal, PhD, NIZO food research B.V
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTB2022TN106
- 200918 (Other Identifier: CRO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.